These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19467675)

  • 1. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132.
    Eggener SE; Raman JD
    J Urol; 2009 Jul; 182(1):396-7. PubMed ID: 19467675
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen.
    Baltaci S; Süer E; Haliloğlu AH; Gokce MI; Elhan AH; Bedük Y
    J Urol; 2009 Jan; 181(1):128-32. PubMed ID: 19012907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active surveillance for prostate cancer: has the time finally come?
    Aragon-Ching JB
    J Clin Oncol; 2010 Jun; 28(16):e265-6; author reply e267. PubMed ID: 20406916
    [No Abstract]   [Full Text] [Related]  

  • 6. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
    Thompson IM; Ankerst DP; Etzioni R; Wang T
    J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.
    Yoon DK; Park HS; Park JY
    J Urol; 2010 Nov; 184(5):2214-5; author reply 2215. PubMed ID: 20864135
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 11. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
    Connolly D; Hutton R; Keane PF
    Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
    [No Abstract]   [Full Text] [Related]  

  • 14. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prostate specific antigen. Its use as a tumor marker for prostate cancer.
    Kantoff PW; Talcott JA
    Hematol Oncol Clin North Am; 1994 Jun; 8(3):555-72. PubMed ID: 8707772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 17. Estimated impact of the prostate cancer prevention trial on population mortality.
    Zeliadt SB; Etzioni R; Kristal AR
    Cancer; 2005 Oct; 104(7):1556-7; author reply 1557. PubMed ID: 16015625
    [No Abstract]   [Full Text] [Related]  

  • 18. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors in prostate cancer. Review of the literature and future perspectives].
    Cussenot O; Ravery V; Desgrandchamps F; Cochand-Priollet B; Teillac P; Le Duc A
    Prog Urol; 1994 Feb; 4(1):17-30. PubMed ID: 7514473
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. B. J. Trock, C. C. Guo, M. L. Gonzalgo, A. Magheli, S. Loeb and J. I. Epstein. J Urol 2009; 182: 1364-1370.
    Ikenberg K; Zimmermann AK; Kristiansen G
    J Urol; 2010 May; 183(5):2100; author reply 2100-1. PubMed ID: 20359717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.